Global Oral Antibiotics Market Report and Forecast 2024-2032

Global Oral Antibiotics Market Outlook

The global oral antibiotics market size was valued at USD 18.5 billion in 2023, driven by the rising incidence of infectious diseases across the globe. The market is expected to grow at a CAGR of 2.5% during the forecast period of 2024-2032, with the values likely to rise from USD 18.96 billion in 2024 to USD 23.1 billion by 2032.

Oral Antibiotics: Introduction

Oral antibiotics refer to medical drugs such as tablets and capsules that are administered orally and are used to treat mild to moderate infections in the body. They eliminate the risk of canula-related infections to enhance the cost-effectiveness while effectively treating infectious diseases. Moreover, oral antibiotics are typically used to kill microbes in the body.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Oral Antibiotics Market Analysis

With the rising incidence of chronic diseases like influenza and tuberculosis, the oral antibiotics market demand has grown in the historical period. The growing prevalence of urinary tract infections (UTIs), especially in women, has significantly boosted the demand for oral antibiotics such as Fosfomycin and ceftriaxone, among others.

With the sudden COVID-19 outbreak, the approvals for oral antibiotics by government bodies have seen an upswing. This can be attributed to enhance the treatment options for infectious diseases. In September 2023, the FDA granted its approval for Canada based Appili Therapeutics' liquid form of antibiotic drug called metronidazole. This liquid oral form is an effective alternative for those who are unable to administer antibiotics through injections or pills.

The oral antibiotics market growth is further driven by a profound emphasis on battling antibiotic resistance. A global non-profit organization CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has awarded the researchers from the University of Melbourne with a whopping USD 1.75 million to develop an oral therapeutic that can restore the activity of antibiotics used to treat pneumonia. Such investments are expected to foster innovation and bring effective treatment alternatives for patients across the globe.

Global Oral Antibiotics Market Segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Class

• Penicillin’s

• Cephalosporins

• Macrolides

• Fluoroquinolones

• Tetracyclines

• Sulfonamides and Trimethoprim

• Others

Market Breakup by Spectrum of Antibiotics

• Broad Spectrum Antibiotics

• Mid and Narrow Spectrum Antibiotics

Market Breakup by Applications

• Respiratory Infections

• Urinary Tract Infections (UTIs)

• Skin Infections

• Gastrointestinal Infections

• Sexually Transmitted Infections (STIs)

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies and Drug Stores

• Online Pharmacies

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Oral Antibiotics Market Overview

The North America, particularly the United States, has dominated the oral antibiotics market share in the historical period. The market share can be accredited to the increasing number of drug approvals by the government bodies like the FDA. Furthermore, the region is experiencing several mergers and acquisitions wherein the healthcare giants are acquiring smaller companies to foster innovation and growth.

The Asia Pacific region is anticipated to experience a surge in the oral therapeutics market value, aided by improving research and healthcare infrastructure. In addition, the rising privatization in countries like India is driving the market forward with rapid adoption of latest technologies. There is immense focus on combating antibiotic resistance, with new seminars being arranged to educate the scientific community.

Europe, with a robust research infrastructure, is another centre of innovation for the oral antibiotics market. It is a huge market for oral antibiotic consumption, with a substantial amount of geriatric population, that is more prone to chronic diseases. The presence of several academic institutions and prominent pharmaceutical companies plays a major role in contributing to the significant market size.

Global Oral Antibiotics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Pfizer Inc.

• Novartis AG

• GlaxoSmithKline plc (GSK)

• Merck & Co., Inc.

• AstraZeneca plc.

• Roche Holding AG

• Bayer AG

• Johnson & Johnson

• Sanofi

• Alkem Laboratories Ltd.

• Cipla Ltd.

• Abbott Laboratories

• Lupin

• Sun Pharmaceutical Industries Ltd.

• Teva Pharmaceutical Industries Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report